Interaction between COVID-19 Infection and Hematological Malignancies --Review.
10.19746/j.cnki.issn.1009-2137.2025.03.046
- Author:
Zi-Heng WANG
1
;
Jia-Yi ZHAO
1
;
Xiao-Feng SHI
1
Author Information
1. Nanjing Medical University, Nanjing 211166, Jiangsu Province, China.
- Publication Type:English Abstract
- Keywords:
coronavirus disease 2019;
hematological malignancies;
COVID-19 vaccine;
prognosis
- MeSH:
Humans;
COVID-19/complications*;
Hematologic Neoplasms/complications*;
SARS-CoV-2
- From:
Journal of Experimental Hematology
2025;33(3):922-926
- CountryChina
- Language:Chinese
-
Abstract:
The pandemic of coronavirus disease 2019 (COVID-19) has impacted our lifestyles. On the one hand, the patients with hematological malignancies (HM) are more vulnerable to COVID-19 infection. Once infected with COVID-19, these patients tend to develop into severe type with a higher mortality rate. Although patients with HM demonstrated a reduced response to COVID-19 vaccines, they still can benefit from vaccine injection with reduced rates of viral infection and incidence of severe cases. The combination of monoclonal antibodies and antiviral drugs is helpful to the COVID-19 treatment of patients with HM. On the other hand, COVID-19 infection can lead to a delay of hematopoietic recovery and low immunity in patients with HM. For HM patients with COVID-19 infection, to reduce the intensity and shorten the course of radiotherapy and chemotherapy is needed. This article will review the interaction between COVID-19 infection and HM.
